Key Takeaway: Dr. Michael Andreeff is a distinguished Professor of Medicine at the University of Texas MD Anderson Cancer Center, where he holds the Paul and Mary Haas Chair in Genetics. He has a notable focus on drug resistance in hematopoietic malignancies, particularly acute myelogenous leukemia (AML), and has contributed to the development of several new therapeutic agents. His extensive training includes degrees from the University of Heidelberg and faculty roles at Memorial Sloan-Kettering Cancer Center.
Price reaction · baseline $4.4 (2023-12-01 close) · 7 other SNTI headline(s) in the window, move may be shared
day 0 close
-1.6%
Market Sentiment Analysis
POSITIVE FACTORS
Dr. Andreeff has made significant contributions to drug resistance research.
He has developed several new therapeutic agents for hematopoietic malignancies.
His academic credentials and positions enhance his credibility in the field.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS
Full Press Release Details
Dr. Andreeff is a Professor of Medicine and holds the Paul and Mary Haas Chair in Genetics at the University of Texas MD Anderson Cancer Center. He has worked extensively on drug resistance in hematopoietic malignancies, such as acute myelogenous leukemia (AML), and developed or co-developed several new therapeutic agents. Dr. Andreeff has an MD and PhD from the University of Heidelberg Medical School, and additional training and faculty appointments at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York in the Departments of Pathology and Leukemia.
Frequently Asked Questions
What is Dr. Andreeff's current position?
Dr. Andreeff is a Professor of Medicine at the University of Texas MD Anderson Cancer Center.
What are Dr. Andreeff's research focuses?
He focuses on drug resistance in hematopoietic malignancies, especially AML.
Where did Dr. Andreeff receive his training?
He trained at the University of Heidelberg Medical School and MSKCC in New York.
What has Dr. Andreeff developed?
He has developed or co-developed several new therapeutic agents for cancer.